We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
Read MoreHide Full Article
Investors have multiple reasons to cheer the Pfizer Inc. (PFE - Free Report) stock as several positive updates about the Pfizer and BioNTech SE (BNTX - Free Report) COVID-19 vaccine have hit the market. To begin with, the FDA has broadened the emergency use authorization (EUA) approval of the COVID-19 vaccine booster shot to adults aged 18 and above. The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has also issued a recommendation suggesting a booster dose. In fact, all the 11 ACIP members unanimously recommended the booster dose.
In another development, Pfizer has announced positive results from a longer-term analysis of their COVID-19 vaccine’s safety and efficacy levels in individuals aged 12 through 15 years. Per the new findings from the companies’ pivotal Phase 3 trial, a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) delivered 100% effectiveness against COVID-19, measured seven days through over four months after the second dose.
Market participants willing to ride Pfizer’s gains from the latest nod on the booster shots can consider ETFs like iShares U.S. Pharmaceuticals ETF (IHE - Free Report) , First Trust Morningstar Dividend Leaders Index Fund (FDL - Free Report) , iShares Evolved U.S. Innovative Healthcare ETF and Invesco Dynamic Pharmaceuticals ETF (PJP - Free Report) .
It is important to note that the booster shot can be administered to all individuals aged 18 years and above and have completed the primary vaccination with any of the authorized or approved COVID-19 vaccines. One can opt for the booster shot at least six months post-completion of the second dose of the primary series.
Presently, Pfizer and BioNTech’s Comirnaty stands to be the only COVID-19 vaccine to have received “full” FDA approval for immunization of adults. The approval was granted by the FDA in August 2021. According to the FDA, the approval was provided after evaluating enormous vaccine data covering about 40,000 trial participants and reflecting 91% efficiency in preventing COVID-19 (per a CNBC article).
Pfizer and BioNTech’s vaccine is also authorized for emergency use in children aged six to 11 years as well as adolescents aged 12 years and above in the United States and Canada. It is also authorized for use in adolescents and adults in Europe.
ETFs to Shine Bright
The full FDA approval has been increasing the confidence for imposing vaccine mandates. Also, the unvaccinated population is now more likely to opt for vaccinations. Now, the nod for booster shots can likely enhance the confidence toward jabs, resulting in more people opting for the vaccination. This update is going to accelerate demand for coronavirus vaccines and boost the company’s financials.
Considering the important role played by the coronavirus vaccines in Pfizer’s recent earnings results, the latest developments can be a positive for the stock. Interestingly, Pfizer has earned revenues of $24.3 billion in the first nine months from the sale of Comirnaty. It is expected to witness total sales of roughly $36 billion at the end of 2021. The early receipt of regulatory authorization for paediatrics and adolescents in the United States has put Pfizer and BioNTech in an advantageous position to gain a lead in the COVID-19 vaccine space. Pfizer expects to generate total sales of approximately $29 billion by delivering 1.7 billion doses of Comirnaty in 2022.
Thus, let’s take a look at ETFs with high exposure to Pfizer that can gain from the recent development:
iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF provides exposure to U.S. companies that manufacture prescription or over-the-counter drugs or vaccines.
iShares U.S. Pharmaceuticals ETF 47 stocks in its basket, with Pfizer making up 21.7% share. The product has AUM of about $384.4 million. iShares U.S. Pharmaceuticals ETF charges 42 basis points (bps) in fees and expenses (read: Wave of Solid Q3 Earnings Push Pharma ETFs Higher).
First Trust Morningstar Dividend Leaders Index Fund
First Trust Morningstar Dividend Leaders Index Fund replicates as closely as possible, before fees and expenses, the price and yield of the Morningstar Dividend Leaders Index and holds 100 stocks in its basket.
Pfizer holds 6.6% weight in the fund. The product has amassed $1.67 billion in its asset base. First Trust Morningstar Dividend Leaders Index Fund has an expense ratio of 0.45%.
iShares Evolved U.S. Innovative Healthcare ETF
iShares Evolved U.S. Innovative Healthcare ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector and holds 248 stocks in its basket, with Pfizer making up for a 7.7% share.
Invesco Dynamic Pharmaceuticals ETF seeks investment results that correspond generally to the price and yield, before fees and expenses, of the Dynamic Pharmaceutical Intellidex Index and holds 23 stocks in its basket, with Pfizer making up for a 6.5% share.
Invesco Dynamic Pharmaceuticals ETF has AUM of about $437.4 million. The fund charges 58 bps in fees and expenses.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Will Pfizer ETFs Soar on Positive COVID-19 Vaccine Updates?
Investors have multiple reasons to cheer the Pfizer Inc. (PFE - Free Report) stock as several positive updates about the Pfizer and BioNTech SE (BNTX - Free Report) COVID-19 vaccine have hit the market. To begin with, the FDA has broadened the emergency use authorization (EUA) approval of the COVID-19 vaccine booster shot to adults aged 18 and above. The U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) has also issued a recommendation suggesting a booster dose. In fact, all the 11 ACIP members unanimously recommended the booster dose.
In another development, Pfizer has announced positive results from a longer-term analysis of their COVID-19 vaccine’s safety and efficacy levels in individuals aged 12 through 15 years. Per the new findings from the companies’ pivotal Phase 3 trial, a two-dose series of the Pfizer-BioNTech COVID-19 Vaccine (30-µg per dose) delivered 100% effectiveness against COVID-19, measured seven days through over four months after the second dose.
Market participants willing to ride Pfizer’s gains from the latest nod on the booster shots can consider ETFs like iShares U.S. Pharmaceuticals ETF (IHE - Free Report) , First Trust Morningstar Dividend Leaders Index Fund (FDL - Free Report) , iShares Evolved U.S. Innovative Healthcare ETF and Invesco Dynamic Pharmaceuticals ETF (PJP - Free Report) .
It is important to note that the booster shot can be administered to all individuals aged 18 years and above and have completed the primary vaccination with any of the authorized or approved COVID-19 vaccines. One can opt for the booster shot at least six months post-completion of the second dose of the primary series.
Presently, Pfizer and BioNTech’s Comirnaty stands to be the only COVID-19 vaccine to have received “full” FDA approval for immunization of adults. The approval was granted by the FDA in August 2021. According to the FDA, the approval was provided after evaluating enormous vaccine data covering about 40,000 trial participants and reflecting 91% efficiency in preventing COVID-19 (per a CNBC article).
Pfizer and BioNTech’s vaccine is also authorized for emergency use in children aged six to 11 years as well as adolescents aged 12 years and above in the United States and Canada. It is also authorized for use in adolescents and adults in Europe.
ETFs to Shine Bright
The full FDA approval has been increasing the confidence for imposing vaccine mandates. Also, the unvaccinated population is now more likely to opt for vaccinations. Now, the nod for booster shots can likely enhance the confidence toward jabs, resulting in more people opting for the vaccination. This update is going to accelerate demand for coronavirus vaccines and boost the company’s financials.
Considering the important role played by the coronavirus vaccines in Pfizer’s recent earnings results, the latest developments can be a positive for the stock. Interestingly, Pfizer has earned revenues of $24.3 billion in the first nine months from the sale of Comirnaty. It is expected to witness total sales of roughly $36 billion at the end of 2021. The early receipt of regulatory authorization for paediatrics and adolescents in the United States has put Pfizer and BioNTech in an advantageous position to gain a lead in the COVID-19 vaccine space. Pfizer expects to generate total sales of approximately $29 billion by delivering 1.7 billion doses of Comirnaty in 2022.
Thus, let’s take a look at ETFs with high exposure to Pfizer that can gain from the recent development:
iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF provides exposure to U.S. companies that manufacture prescription or over-the-counter drugs or vaccines.
iShares U.S. Pharmaceuticals ETF 47 stocks in its basket, with Pfizer making up 21.7% share. The product has AUM of about $384.4 million. iShares U.S. Pharmaceuticals ETF charges 42 basis points (bps) in fees and expenses (read: Wave of Solid Q3 Earnings Push Pharma ETFs Higher).
First Trust Morningstar Dividend Leaders Index Fund
First Trust Morningstar Dividend Leaders Index Fund replicates as closely as possible, before fees and expenses, the price and yield of the Morningstar Dividend Leaders Index and holds 100 stocks in its basket.
Pfizer holds 6.6% weight in the fund. The product has amassed $1.67 billion in its asset base. First Trust Morningstar Dividend Leaders Index Fund has an expense ratio of 0.45%.
iShares Evolved U.S. Innovative Healthcare ETF
iShares Evolved U.S. Innovative Healthcare ETF employs data science techniques to identify companies with exposure to the innovative healthcare sector and holds 248 stocks in its basket, with Pfizer making up for a 7.7% share.
iShares Evolved U.S. Innovative Healthcare has AUM of about $41.9 million. The fund charges 18 bps in fees and expenses (read: JNJ Posts Mixed Q3 Bag, Ups View: ETFs in Focus).
Invesco Dynamic Pharmaceuticals ETF
Invesco Dynamic Pharmaceuticals ETF seeks investment results that correspond generally to the price and yield, before fees and expenses, of the Dynamic Pharmaceutical Intellidex Index and holds 23 stocks in its basket, with Pfizer making up for a 6.5% share.
Invesco Dynamic Pharmaceuticals ETF has AUM of about $437.4 million. The fund charges 58 bps in fees and expenses.